NEW YORK, NY--(Marketwire - May 25, 2012) - Daxor Corporation (NYSE MKT: [ DXR ]) (NYSE Amex: [ DXR ]), an investment company with medical instrumentation and biotechnology operations, filed a Form N-Q today disclosing its schedule of portfolio holdings as of March 31, 2012. The next Form N-Q will be filed as of September 30, 2012 before the end of November 2012.

Daxor has begun reporting as an investment company effective January 1, 2012. The Company's next public report will be a Form N-CSR which will be for the six months ended June 30, 2012 and will be filed before the end of August 2012. The Company will also be filing a Form N-CSR for the year ended December 31, 2012 before the end of February 2013.

For the three months ended March 31, 2012, the Company's revenue from the sale of Volumex Kits increased by 12% from the quarter ended March 31, 2011. There were 64 Blood Volume Analyzers in service at March 31, 2012 versus 56 instruments at March 31, 2011. There will be additional disclosure regarding the Company's Volumex Kit Sales and other operations in the Form N-CSR for the six months ended June 30, 2012.

Dr. Joseph Feldschuh, the President of Daxor, said: "We don't know if this improvement in the sale of Volumex Kits will continue. We realize there are no guarantees but remain hopeful that members of the medical community will understand the need for measuring patients' blood volume precisely rather than using surrogate tests and clinical guesstimates which can be grossly inaccurate."